



PEPTIDE SYNTHESIS

Almac has the most unique and extensive range of integrated drug development services available to the pharmaceutical & biotech industry. Employing over 2,600 highly skilled individuals, the privately owned organisation is headquartered in Craigavon, Northern Ireland, UK and has extensive facilities in the US. Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their needs. Our world class pharmaceutical solutions extend from research, through clinical development to the commercialisation of product.

RAPIDD™ (Accelerated Process Integrated Drug Development) is a **First in Man** package including:

- Non GMP tox batch of peptide API
- Process development
- Full analytical development and validation
- cGMP batch production
- Stability studies (ICH)
- Formulation Development
- Pre-clinical safety assessment
- Regulatory support (CTA/IND submission)

Almac offers cGMP peptide synthesis from preclinical to commercial supplies

Connectivity between the peptide offering and other

Almac Services includes:

- ¹⁴C Radiolabeling
- Cytotoxic conjugation
- Sterile formulation and filling

Synthesis of sophisticated peptides:

- Therapeutic Peptides (conforming to GMP ICHQ7A)
- Long peptides (40-180mer)
- Chemokines (including site specifically labelled)



rapidd™
Accelerated Process Integrated Drug Development

Accelerate entry to Phase I clinical trials

- cGMP peptide/API synthesis
- Full analytical package
- Pre-clinical safety assessment
- Formulation including sterile fill
- Regulatory documentation

For European Enquiries:

Almac Sciences
Almac House
20 Seagoe Industrial Estate, Craigavon,
BT63 5QD, United Kingdom.

T: +44 (0) 28 3833 2200

E: sciences@almacgroup.com

www.almacgroup.com

For American Enquiries:

Almac Sciences
2661 Audubon Road,
Audubon, PA 19403,
United States of America.

T: +1 (610) 755 7621

E: sciences@almacgroup.com